November 16, 2020

Initiatives Against COVID-19 in Canada - Initiate Phase 2/3 Clinical Trials of VLP Vaccine Candidate -

Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka, Japan; President & Representative Director; Hiroaki Ueno) announced today that its affiliated company, Medicago Inc. (Head Office: Quebec, Canada; CEO; Bruce D. Clark) and GlaxoSmithKline (Head Office: London, United Kingdom; hereafter, "GSK") announced on November 12 local time the start of Phase 2/3 clinical trials for its plant-derived virus-like particle (VLP) vaccine candidate (project code: MT-2766) for the prevention of coronavirus disease 2019 (COVID-19) which is being developed by Medicago.

The summaries of the Phase 2/3 clinical studies are as follows:

[Phase 2 trial]

■Subjects: 600 healthy adults aged 18-64 and elderly adults over 65 in Canada and the United States.

■ Dosage and administration: Two doses of 3.75 μg VLP vaccine candidate combined with GSK's adjuvant given 21 days apart.

■Endpoints: Safety and immunogenicity. (compared to placebo)

[Phase 3 trial]

■Subjects: 30,000 subjects in North America, Latin America and/or Europe

■ Dosage and administration: Two doses of 3.75 μg VLP vaccine candidate combined with GSK's adjuvant given 21 days apart.

■Endpoints: Efficacy and safety. (compared to placebo)

■Schedule: Plans to start before the end of 2020.

Mitsubishi Tanabe Pharma Group will work to develop and deliver MT-2766 to society as soon as possible, contributing even further to the prevention of COVID-19, a pressing social issue.

Medicago release (November 12, 2020, local time)
Medicago and GSK announce start of Phase 2/3 clinical trials of adjuvanted COVID-19 vaccine candidate.

Mitsubishi Tanabe Pharma Corporation
Corporate Communications Department
Media contacts: TEL:+81 6 6205 5119